Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa

Journal of Antibiotics

Volumn 66, Issue 2, 2013, Pages 99-101

  Hennessy, Emma ^a   Mooij, Marlies J ^a   Legendre, Claire ^a   Jerry Reen, F ^a   O'Callaghan, Julie ^a   Adams, Claire ^a   O'Gara, Fergal ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

biofilm; motility; Pseudomonas aeruginosa; statins

Indexed keywords

COMPACTIN; CRYSTAL VIOLET; MEVINOLIN; SIMVASTATIN; VIRULENCE FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BIOFILM; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; TWITCHING MOTILITY;

ANTI-BACTERIAL AGENTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; VIRULENCE;

EID: 84874629217     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2012.95     Document Type: Article

References (21)

1. Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001). (Pubitemid 32440937)
2. Almog, Y. et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110, 880-885 (2004). (Pubitemid 39096018)
3. Schlienger, R. G., Fedson, D. S., Jick, S. S., Jick, H. & Meier, C. R. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27, 325-332 (2007). (Pubitemid 46327900)
4. Mortensen, E. M., Restrepo, M. I., Anzueto, A. & Pugh, J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir. Res. 6, 82 (2005).
5. Jerwood, S. & Cohen, J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother. 61, 362-364 (2008).
6. Bergman, P. et al. Studies on the antibacterial effects of statins-in vitro and in vivo. Plos One 6, e24394 (2011).
7. Welsh, A. M., Kruger, P. & Faoagali, J. Antimicrobial action of atorvastatin and rosuvastatin. Pathology 41, 689-691 (2009).
8. Rosch, J. W. et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J. Clin. Invest. 120, 627-635 (2010).
9. Govan, J. R. & Deretic, V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60, 539-574 (1996). (Pubitemid 26303478)
10. Williams, B. J., Dehnbostel, J. & Blackwell, T. S. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15, 1037-1056 (2010).
11. Holloway, B. W., Krishnapillai, V. & Morgan, A. F. Chromosomal genetics of Pseudomonas. Microbiol. Rev. 43, 73-102 (1979). (Pubitemid 9169387)
12. Liberati, N. T. et al. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc. Natl. Acad. Sci. USA 103, 2833-2838 (2006).
13. O'Toole, G. A. & Kolter, R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30, 295-304 (1998). (Pubitemid 28480181)
14. Glessner, A., Smith, R. S., Iglewski, B. H. & Robinson, J. B. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of twitching motility. J. Bacteriol. 181, 1623-1629 (1999). (Pubitemid 29110824)
15. Ravn, L., Christensen, A. B., Molin, S., Givskov, M. & Gram, L. Methods for detecting acylated homoserine lactones produced by Gram-negative bacteria and their application in studies of AHL-production kinetics. J. Microbiol. Methods 44, 239-251 (2001). (Pubitemid 32182376)
16. Breidenstein, E. B., de la Fuente-Nunez, C. & Hancock, R. E. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19, 419-426 (2011).
17. Jouneau, S. et al. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. Plos One 6, e22655 (2011).
18. Chen, Y. J. et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int. Immunopharmacol. 10, 685-693 (2010).
19. Konstan, M. W. et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediat. Pulm. 46, 230-238 (2010).
20. Konstan, M. W. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J. Cyst. Fibros. 10, 54-61 (2011).
21. Feng, L. et al. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae. Bioorg. Med. Chem. 19, 3512-3519 (2011).